Form 4 for RYTM RHYTHM PHARMACEUTICALS, INC.
Accepted 2026-08-17 18:00:24 ET · period of report 2026-08-13 · accession 0001649904-26-000015 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-17 18:00 | 2026-08-13 | RYTM | Shulman Joseph | Chief Technical Off | M - OptEx | $6.80 | +2,024 | 21.0K | +11% | +$13.8K |
| DT | 2026-08-17 18:00 | 2026-08-13 | RYTM | Shulman Joseph | Chief Technical Off | S - Sale+OE | $119.75 | -5,079 | 15.9K | -24% | -$608.2K |
| DT | 2026-08-17 18:00 | 2026-08-13 | RYTM | Shulman Joseph | Chief Technical Off | M - OptEx | $0.00 | -2,024 | 5,945 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-13 | M | A | 2,024 | $6.80 | 20,994 | D | — | — | (F1) The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. |
| 2 | Common | Common Stock | 2026-08-13 | S | D | 5,079 | $119.75 | 15,915 | D | — | — | (F1) The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. |
| 3 | Derivative | Stock Options (Right to Buy) | 2026-08-13 | M | D | 2,024 | $0.00 | 5,945 | D | $6.80 · — to 2032-02-08 | 2,024 Common Stock | (F1) The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. (F2) The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |